Veerle de Pril

7.5k total citations
26 papers, 1.5k citations indexed

About

Veerle de Pril is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Veerle de Pril has authored 26 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 13 papers in Molecular Biology and 8 papers in Immunology. Recurrent topics in Veerle de Pril's work include CAR-T cell therapy research (20 papers), Cancer Immunotherapy and Biomarkers (16 papers) and Melanoma and MAPK Pathways (10 papers). Veerle de Pril is often cited by papers focused on CAR-T cell therapy research (20 papers), Cancer Immunotherapy and Biomarkers (16 papers) and Melanoma and MAPK Pathways (10 papers). Veerle de Pril collaborates with scholars based in United States, Italy and Belgium. Veerle de Pril's co-authors include Jeffrey S. Weber, Célèste Lebbé, Reinhard Dummer, Michele Maio, Jedd D. Wolchok, F. Stephen Hodi, Vanna Chiarion‐Sileni, Rachel Humphrey, Steven O’Day and Ramy Ibrahim and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and British Journal of Cancer.

In The Last Decade

Veerle de Pril

26 papers receiving 1.4k citations

Peers

Countries citing papers authored by Veerle de Pril

Since Specialization

Citations

This map shows the geographic impact of Veerle de Pril's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Veerle de Pril with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Veerle de Pril more than expected).

Fields of papers citing papers by Veerle de Pril

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Veerle de Pril. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Veerle de Pril. The network helps show where Veerle de Pril may publish in the future.

Co-authorship network of co-authors of Veerle de Pril

This figure shows the co-authorship network connecting the top 25 collaborators of Veerle de Pril. A scholar is included among the top collaborators of Veerle de Pril based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Veerle de Pril. Veerle de Pril is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1076O Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238 2020 ·Annals of Oncology ·Jeffrey S. Weber, Michele Del Vecchio, Mario Mandalà, Helen Gogas, Ana Arance, Stéphane Dalle, C. Lance Cowey, Michael Schenker, Jean‐Jacques Grob, (unknown), Iván Márquez‐Rodas, Marcus O. Butler, Michele Maio, Mark R. Middleton, Luis de la Cruz‐Merino, Maurice Lobo, Veerle de Pril, James Larkin, Paolo A. Ascierto	6
2	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial 2019 ·European Journal of Cancer ·Alexander M.M. Eggermont, Vanna Chiarion‐Sileni, Jean-Jacques Grob, Reinhard Dummer, Jedd D. Wolchok, Henrik Schmidt, Omid Hamid, Caroline Robert, Paolo A. Ascierto, Jon Richards, Célèste Lebbé, Virginia Ferraresi, Michael Smylie, Jeffrey S. Weber, Michele Maio, Fareeda Hosein, Veerle de Pril, Michal Kiciński, Stefan Suciu, Alessandro Testori	123
3	Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study 2019 ·The Journal of Dermatology ·Kenji Yokota, Hiroshi Uchi, Hisashi Uhara, Shusuke Yoshikawa, Tatsuya Takenouchi, Takashi Inozume, Kentaro Ozawa, Hironobu Ihn, Yasuhiro Fujisawa, Anila Qureshi, Veerle de Pril, Yasushi Otsuka, Jeffrey S. Weber, Naoya Yamazaki	13
4	Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial. 2019 ·Journal of Clinical Oncology ·Alexander Eggermont, Vanna Chiarion‐Sileni, Jean‐Jacques Grob, Reinhard Dummer, Jedd D. Wolchok, Henrik Schmidt, Omid Hamid, Caroline Robert, Paolo A. Ascierto, Jon Richards, Célèste Lebbé, Virginia Ferraresi, Michael Smylie, Jeffrey S. Weber, Michele Maio, Fareeda Hosein, Veerle de Pril, Michal Kiciński, Stefan Suciu, Alessandro Testori	14
5	Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Updated results from a phase 3 trial (CheckMate 238) 2018 ·British Journal of Cancer ·(unknown), Mario Mandalà, M. Del Vecchio, Helen Gogas, Ana Arance, C. Lance Cowey, Stéphane Dalle, (unknown), Vanna Chiarion‐Sileni, Iván Márquez‐Rodas, Jean‐Jacques Grob, Marcus O. Butler, Mark R. Middleton, Michele Maio, Victoria Atkinson, R. Dummer, Veerle de Pril, Anila Qureshi, James Larkin, P.A. Ascierto	1
6	Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238). 2018 ·Journal of Clinical Oncology ·Jeffrey S. Weber, Mario Mandalà, Michele Del Vecchio, Helen Gogas, Ana Arance, C. Lance Cowey, Stéphane Dalle, Michael Schenker, Vanna Chiarion‐Sileni, Iván Márquez‐Rodas, Jean‐Jacques Grob, Marcus O. Butler, Mark R. Middleton, Michele Maio, Victoria Atkinson, Reinhard Dummer, Veerle de Pril, Anila Qureshi, James Larkin, Paolo A. Ascierto	52
7	Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238) 2017 ·Annals of Oncology ·Jeffrey S. Weber, Mario Mandalà, Michele Del Vecchio, Helen Gogas, Ana Arance, (unknown), Stéphane Dalle, Michael Schenker, Vanna Chiarion‐Sileni, Iván Márquez‐Rodas, Jean‐Jacques Grob, Marcus O. Butler, Mark R. Middleton, Michele Maio, Victoria Atkinson, Paola Queirolo, Veerle de Pril, Anila Qureshi, James Larkin, Paolo A. Ascierto	3
8	A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence 2015 ·Journal for ImmunoTherapy of Cancer ·Jeffrey S. Weber, Jean‐Jacques Grob, Kim Margolin, Paolo A. Ascierto, Mario Sznol, Patrick A. Ott, (unknown), Veerle de Pril, Mary Ruisi, F. Stephen Hodi	6
9	Efficacy, Safety, and Quality of Life (Qol) Data from the Eortc 18071 Phase III Trial of Ipilimumab (Ipi) Versus Placebo After Complete Resection of Stage III Melanoma 2014 ·Annals of Oncology ·Alexander Eggermont, Vanna Chiarion‐Sileni, Jean‐Jacques Grob, Reinhard Dummer, Jedd D. Wolchok, Henrik Schmidt, Omid Hamid, Caroline Robert, Paolo A. Ascierto, Jon Richards, Célèste Lebbé, Virginia Ferraresi, Michael Smylie, Jeffrey S. Weber, Michele Maio, Cyril Konto, Ravichandra Karra Gurunath, Veerle de Pril, Stefan Suciu, Alessandro Testori	4
10	Patterns of onset and resolution of immune‐related adverse events of special interest with ipilimumab 2013 ·Cancer ·Jeffrey S. Weber, Reinhard Dummer, Veerle de Pril, Célèste Lebbé, F. Stephen Hodi, (unknown)	340
11	Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials 2013 ·Annals of Oncology ·Jedd D. Wolchok, Jeffrey S. Weber, Michele Maio, Bart Neyns, Kaan Harmankaya, Kevin M. Chin, (unknown), Veerle de Pril, Rachel Humphrey, Célèste Lebbé	139
12	CA184-156: A randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) plus etoposide/platinum (EP) versus EP in subjects with newly diagnosed extensive-stage disease small cell lung cancer (ED-SCLC). 2012 ·Journal of Clinical Oncology ·David R. Spigel, Christoph Zielinski, Sabine Maier, Veerle de Pril, Justin Fairchild, Jean-Marie Cuillerot, Martin Reck	7
13	Clinical response to ipilimumab: Effect of systemic corticosteroids used to manage immune-related adverse events (irAEs) 2010 ·Annals of Oncology ·Paul Lorigan, Jeff Sosman, J.B.A.G. Haanen, Jose Lutzky, David Hogg, M. Gore, W J Urba, Veerle de Pril, (unknown), J. D. Wolchok	5
14	Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study 2010 ·Annals of Oncology ·Steven O’Day, Michele Maio, Vanna Chiarion‐Sileni, Thomas F. Gajewski, Hubert Pehamberger, Igor Bondarenko, Paola Queirolo, Lisa Lundgren, (unknown), Laslo Roman, Claire F. Verschraegen, Rachel Humphrey, Ramy Ibrahim, Veerle de Pril, Axel Hoos, Jedd D. Wolchok	415
15	Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. 2010 ·PubMed ·Jedd D. Wolchok, Jeffrey S. Weber, Omid Hamid, Célèste Lebbé, Michele Maio, Dirk Schadendorf, Veerle de Pril, Kevin N. Heller, Tai‐Tsang Chen, Ramy Ibrahim, Axel Hoos, Steven O’Day	95
16	Efficacy of ipilimumab 10 mg/kg in advanced melanoma patients (pts) with good and poor prognostic factors 2009 ·Journal of Clinical Oncology ·Jedd D. Wolchok, Veerle de Pril, Gerald P. Linette, William Waterfield, Thomas F. Gajewski, Vanna Chiarion‐Sileni, Ramy Ibrahim, Kevin M. Chin, Axel Hoos, Omid Hamid	4
17	9312 Antitumor responses to ipilimumab in advanced melanoma are not affected by systemic corticosteroids used to manage immune-related adverse events (irAEs) 2009 ·European Journal of Cancer Supplements ·Jean‐Jacques Grob, Omid Hamid, Jedd D. Wolchok, Michele Maio, Bart Neyns, Linzi Thomas, Veerle de Pril, (unknown), (unknown), Célèste Lebbé	7
18	Coadministration of muraglitazar plus glyburide: Improvement of glycaemic and lipid profiles in patients with type 2 diabetes 2009 ·Diabetes and Vascular Disease Research ·Cindy J. Rubin, Veerle de Pril, Fred T. Fiedorek	2
19	Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials 2009 ·Journal of Clinical Oncology ·Jose Lutzky, J. D. Wolchok, Omid Hamid, Célèste Lebbé, Hubert Pehamberger, Gerald P. Linette, Veerle de Pril, Ramy Ibrahim, Axel Hoos, Steven O’Day	49
20	Cefepime vs. ceftazidime treatment of pyelonephritis: a European, randomized, controlled study of 300 pediatric cases 1998 ·The Pediatric Infectious Disease Journal ·Urs B. Schaad, Juhani Eskola, (unknown), (unknown), Shai Ashkenazi, Vassiliki Syriopoulou, (unknown), Veerle de Pril, (unknown), C. Rollin	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact